rs2228145 — IL6R Asp358Ala

IL-6 Receptor Asp358Ala — The Variant That Splits Your Immune System's Priorities

The interleukin-6 receptor is one of the most clinically targeted proteins in modern medicine. IL-6 sits at the center of the acute-phase immune response, coordinating everything from C-reactive protein production to T cell differentiation. The Asp358Ala missense variant — a single amino acid swap from aspartate to alanine at position 358 in the IL6R protein — reshapes how the receptor is shed from the cell surface, with downstream consequences that run in exactly opposite directions depending on which disease you're considering.

The Mechanism

IL6R encodes the alpha subunit of the interleukin-6 receptor (CD126). Signaling normally requires this membrane-bound receptor to bind IL-6, then recruit the co-receptor gp130 (IL6ST) to activate JAK1/STAT3 pathways — called classical signaling¹¹ classical signaling
Classical IL-6 signaling is restricted to cells that express membrane-bound IL6Rα: hepatocytes, monocytes, and certain lymphocytes. It drives the acute-phase response, CRP production, and pro-inflammatory T cell priming.

A soluble form of IL6Rα (sIL-6R) is continuously shed from cell surfaces by the ADAM10 and ADAM17 metalloproteases. This soluble receptor enables trans-signaling²² trans-signaling
Trans-signaling allows IL-6 to activate cells that do not express membrane-bound IL6R — including endothelial cells, smooth muscle cells, and neurons — dramatically broadening IL-6's reach and altering immune polarization in ways classical signaling cannot. The Asp358Ala substitution sits near the cleavage site recognized by ADAM proteases and substantially increases ectodomain shedding efficiency.

The result is a shift in the IL-6 signaling balance: carriers of the C allele (358Ala) produce approximately 34.6% more sIL-6R per allele while simultaneously reducing membrane IL6Rα density on CD4+ T cells and monocytes by up to 28% per allele. Classical signaling — the arm that drives CRP production and pro-inflammatory Th17 polarization — is impaired. Trans-signaling — the arm that reaches vascular endothelium and Th2-permissive environments — is enhanced.

The Evidence

The cardiovascular finding came first. The IL6R Genetics Consortium meta-analysis³³ IL6R Genetics Consortium meta-analysis
Sarwar N et al., The Lancet 2012; 82 studies combining 125,222 participants for biomarker analysis and 187,667 for CHD case-control analysis — the largest IL6R study at the time showed that each copy of the 358Ala allele reduces coronary heart disease risk by 3.4% (OR 0.966, 95% CI 0.950–0.982, p=4.5×10⁻⁵). The same allele lowered CRP by 7.5%, fibrinogen by 1.0%, and raised circulating sIL-6R by 34.3%. This study was explicitly designed to mimic the pharmacological effect of tocilizumab using a genetic instrument — and concluded that IL-6R blockade causally reduces CHD risk.

The functional mechanism study⁴⁴ functional mechanism study
Ferreira RC et al., PLoS Genetics 2013: cell-based experiments in primary human cells, combined with large-scale genetic association across multiple inflammatory diseases confirmed that 358Ala impairs classical IL-6 signaling at the receptor-cell interface. In CD4+ T cells and monocytes, each C allele reduces surface IL6R expression by up to 28% and impairs downstream STAT3 and STAT1 phosphorylation (p≤5.2×10⁻⁷). The allele protects against coronary heart disease, rheumatoid arthritis, atrial fibrillation, and abdominal aortic aneurysm — all conditions driven by classical IL-6 signaling and CRP-mediated inflammation. The flip side is increased susceptibility to asthma and type 1 diabetes — conditions where dampened IL-6 suppression of Th2-type immune responses allows IgE-mediated inflammation to amplify.

In asthma specifically, Hawkins et al. (Journal of Allergy and Clinical Immunology, 2012)⁵⁵ Hawkins et al. (Journal of Allergy and Clinical Immunology, 2012)
Cohort study in two independent asthma populations: SARP and CSGA, combined p=0.003 for lung function associations showed the C allele was associated with reduced FEV1, FVC, and FEV1/FVC ratio, and was enriched in severe asthma phenotypic clusters. The mechanism involves enhanced IL-6 trans-signaling promoting eosinophilic airway inflammation rather than the Th17-suppressive effects of classical signaling.

The Ferreira et al. Nature Genetics GWAS (2017)⁶⁶ Ferreira et al. Nature Genetics GWAS (2017)
360,838 participants, 136 independent risk loci for allergic disease across asthma, hay fever, and eczema confirmed rs2228145 as a shared risk locus across all three allergic conditions with equal effect sizes — meaning the IL-6 receptor biology applies to the full atopic spectrum, not just asthma alone.

Practical Implications

For CC homozygotes, the C allele's effect is bidirectional: cardiovascular risk from classical IL-6 signaling is reduced (a benefit), while risk for asthma and other atopic conditions is elevated. Monitoring should be calibrated accordingly — CRP levels will be genetically lower than expected, potentially understating true inflammatory burden during allergic flares. Th2-specific biomarkers (total IgE, eosinophil count, FeNO) are more informative than CRP for tracking atopic inflammation in CC carriers.

For AC heterozygotes, the effects are intermediate and often asymptomatic in isolation, but the IL6R allele contributes to overall atopic burden especially when other allergic risk variants are co-inherited.

The pharmacogenomic implication applies across all genotypes: tocilizumab (anti-IL6R) and sarilumab work by blocking the same receptor this variant modifies. The 358Ala allele changes baseline receptor availability and trans-signaling capacity, making it a plausible predictor of response to IL-6R-blocking biologics — a connection that has been studied but not yet clinically validated for routine genotype-guided dosing.

Interactions

rs12133641, a deep intronic IL6R variant at chr1:154455807, lies approximately 1,313 bp from rs2228145 and is in partial linkage disequilibrium with it. Both variants modify IL6R expression or function, and the complete IL6R haplotype across both sites gives a more complete picture of an individual's IL-6 receptor biology than either variant alone. rs12133641 shows overlapping cardiovascular-protective and atopic-risk associations, though its exact regulatory mechanism (splicing vs. expression) differs from the coding Asp358Ala change.

rs4129267 is another intronic IL6R variant (~39% T allele in Europeans) associated with CRP levels and asthma — likely tagging a partially overlapping functional haplotype.